“People who develop a strong allergic reaction after receiving the first dose of Nuvaxovid should not receive the second”, advocates the European Medicines Agency (EMA).
Le Monde with Reuters
The Novavax COVID-19 vaccine could cause severe allergic reactions (anaphylaxis), according to the latest opinion of the European Medicines Agency (EMA), dating from Thursday, July 14. The product relating to the product will be updated by the agency, so that as possible side effect of the Nuvaxovid vaccine an unusual sensation, or a loss of sensitivity, on the skin. “People who develop a strong allergic reaction after receiving the first dose of Nuvaxovid should not receive the second,” recommends the EMA on its site.
The vaccine was authorized by American regulators on Wednesday, and on the label of the product distributed in the United States is a warning against the administration of the vaccine to people with history of allergic reactions to one of its components.
The American company’s vaccine uses a more classic technique than messenger RNA, that of the recombinant protein, on which for several decades have been based for several decades against hepatitis B, darling or The flu.
an administration rate between 0 and 0.1 %2>
The Novavax vaccine is available in dozens of countries. Only 250,000 doses have been administered in Europe since its launch in December, according to the European Center for Disease Prevention and Control.
In France, it was authorized by the High Authority for Health (HAS) on January 14, 2022 and distributed as a priority in the overseas departments and communities, in the course of February, in order to lift the reluctance to the vaccination due to messenger RNA. The vaccination rate in Nuvaxovid rises at 0.1 % in Martinique, Guadeloupe, Guyana and Reunion, and 0 % in France, according to Maladie insurance data .
The action of the American pharmaceutical group Novavax plunged on the stock market at Wall Street after the publication of the EMA opinion.